Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2021-07-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于获得药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving a drug registration approval from the national drug regulatory authority. It details the drug name, specifications, approval number, and the impact on the company. The document is short (1031 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, nor a call transcript or governance document. It is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-07-01 Chinese
关于公司注射用头孢他啶拟中选第五批全国药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the proposed selection of their product (注射用头孢他啶) in the fifth batch of a national centralized drug procurement. It details the product information, pricing, procurement cycle, and potential impact on the company. The document is short (875 characters) and serves as an announcement of a business development related to product procurement and sales potential, not a financial report or regulatory filing. It does not contain financial statements, audit information, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category about business operations and procurement results, which aligns with Regulatory Filings (RNS).
2021-06-23 Chinese
关于注射用头孢他啶通过仿制药质量和疗效一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company regarding the approval of a drug (injection cefotaxime) passing a generic drug quality and efficacy consistency evaluation by the National Medical Products Administration. It includes details about the drug, its market status, company R&D investment, and the impact on the company. The document is short (1062 characters) and is an announcement of regulatory approval and business impact rather than a financial report or detailed regulatory filing. It does not contain financial statements, management discussion, or detailed governance information. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and business impact that does not fit other specific categories.
2021-06-10 Chinese
关于获得药品补充申请批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving approval for a drug supplement application from the National Medical Products Administration. It details the drug's specifications, approval status, and potential impact on the company. The document is short (935 characters) and serves as an announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or shareholder voting results. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and does not match other specific categories like Annual Report, Earnings Release, or Capital Update.
2021-05-24 Chinese
关于参加浙江辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor collective reception day event, including details about the event date, time, and participants from the company's board and management. It focuses on investor communication and interaction rather than presenting financial data, audit results, or formal reports. The document is short (549 characters) and serves as a notice of an event rather than a report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-05-07 Chinese
2020年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2020 annual equity distribution (dividend) plan of 普洛药业股份有限公司. It details the dividend amount per share, the record date, the ex-dividend date, the dividend recipients, and the method of dividend distribution. It references the shareholders' meeting approval and provides contact information for inquiries. The document is short (1734 characters) and serves as a formal announcement of the dividend payment details rather than a full financial report or annual report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2021-04-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.